Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

被引：30
|
作者：
Zhang, Wen-Ji [1 ,2 ]
Li, Yong [3 ]
Wei, Meng-Ning [1 ,2 ]
Chen, Yao [1 ,2 ]
Qiu, Jian-Ge [1 ,2 ]
Jiang, Qi-Wei [1 ,2 ]
Yang, Yang [1 ,2 ]
Zheng, Di-Wei [1 ,2 ]
Qin, Wu-Ming [1 ,2 ]
Huang, Jia-Rong [1 ,2 ]
Wang, Kun [1 ,2 ]
Zhang, Wen-Juan [4 ]
Wang, Yi-Jun [5 ]
Yang, Dong-Hua [5 ]
Chen, Zhe-Sheng [5 ,6 ]
Shi, Zhi [1 ,2 ]
机构：
[1] Jinan Univ, Dept Cell Biol, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Inst Biomed, Natl Engn Res Ctr Genet Med, Guangdong Prov Key Lab Bioengn Med,Coll Life Sci, Guangzhou 510632, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Gastrointestinal Surg & Gen Surg, Guangzhou 510080, Guangdong, Peoples R China
[4] Jinan Univ, Dept Prevent Med, Coll Med, Guangzhou 510632, Guangdong, Peoples R China
[5] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY 11439 USA
[6] Jinan Univ, Coll Pharm, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China
来源：
CANCER LETTERS | 2017年 / 386卷
基金：
中国国家自然科学基金;
关键词：
Regorafenib; Lapatinib; Targeted therapy; Combination chemotherapy; Colorectal cancer; MULTIDRUG-RESISTANCE; BREAST-CANCER; DRUG-SENSITIVITY; PHASE-3; TRIAL; TUMOR-GROWTH; COLON-CANCER; INHIBITOR; CELLS; COMBINATION; MULTICENTER;
D O I：
10.1016/j.canlet.2016.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo. Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：100 / 109
页数：10
相关论文
共 50 条
  • [41] Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
    Carvalho Santos, Juliana
    Profitos-Peleja, Nuria
    Lima Ribeiro, Marcelo
    Roue, Gael
    CANCERS, 2022, 14 (22)
  • [42] Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
    Wang, Jun
    Lv, Feng-Mei
    Wang, Dong-Li
    Du, Jian-Liang
    Guo, Hai-Yan
    Chen, Hai-Ni
    Zhao, Shou-Jin
    Liu, Zhe-Peng
    Liu, Yu
    MOLECULES, 2020, 25 (03):
  • [43] Antitumor activity of a synthetic agonist of TLR9 in preclinical lung cancer models.
    Wang, D.
    Yu, D.
    Kandimalla, E. R.
    Agrawal, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
  • [44] Antitumor Activity of Spicatoside A by Modulation of Autophagy and Apoptosis in Human Colorectal Cancer Cells
    Kim, Won Kyung
    Pyee, Yuna
    Chung, Hwa-Jin
    Park, Hyen Joo
    Hong, Ji-Young
    Son, Kun Ho
    Lee, Sang Kook
    JOURNAL OF NATURAL PRODUCTS, 2016, 79 (04): : 1097 - 1104
  • [45] Disulfiram-loaded hollow copper sulfide nanoparticles show antitumor effects in preclinical models of colorectal cancer
    Jiapaer, Zeyidan
    Zhang, Lingying
    Ma, Wanli
    Liu, Haoqiang
    Li, Chengyu
    Huang, Weidong
    Shao, Shuxuan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 635 : 291 - 298
  • [46] Antitumor activity in colorectal cancer induced by hinokiflavone
    Zhou, Jing
    Zhao, Rongce
    Ye, Tinghong
    Yang, Shuping
    Li, Yali
    Yang, Fangfang
    Wang, Gang
    Xie, Yongmei
    Li, Qiu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (09) : 1571 - 1580
  • [47] ANTITUMOR AND ANTIANGIOGENIC ACTIVITY OF SORAFENIB ON COLORECTAL CANCER
    Kilickap, S.
    Altun, A.
    Babacan, N. A.
    Ataseven, H.
    Kaya, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [48] ANTITUMOR ACTIVITY OF DIETARY PHYTOCHEMICALS IN COLORECTAL CANCER
    Megna, B.
    Diaz-Diaz, C.
    Carney, P.
    Nukaya, M.
    Kennedy, G.
    DISEASES OF THE COLON & RECTUM, 2015, 58 (05) : E98 - E98
  • [49] Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer
    Bai, Tao
    Dong, Dao-Song
    Pei, Ling
    ONCOLOGY REPORTS, 2014, 31 (05) : 2293 - 2297
  • [50] Synergistic antitumor activity of DHA and JQ1 in colorectal carcinoma
    Ding, Wanjing
    Zhang, Haojian
    Mei, Guangming
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 885
12345